pharmaceutical investing Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial
pharmaceutical investing Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
Bold Reports Positive Results of Induced Polarization Survey at Joutel - Signs Investor Awareness Agreement